|
1
|
Moura Penteado LA, Lucena GM, Brandão
Peixoto MO, Barbosa TC, de Souza Leitão Arruda AC and Cimões R:
Evaluation of the effect of tacrolimus on periodontitis induced in
rats. Arch Oral Biol. 80:89–94. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chien YS, Chen YT, Chuang CH, Cheng YT,
Chuang FR and Hsieh H: Incidence and risk factors of new-onset
diabetes mellitus after renal transplantation. Transplant Proc.
40:2409–2411. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lancia P, Adam de Beaumais T and
Jacqz-Aigrain E: Pharmacogenetics of posttransplant diabetes
mellitus. Pharmacogenomics J. 17:209–221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Montori VM, Basu A, Erwin PJ, Velosa JA,
Gabriel SE and Kudva YC: Posttransplantation diabetes: A systematic
review of the literature. Diabetes Care. 25:583–592. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Demirci MS, Toz H, Yilmaz F, Ertilav M,
Asci G, Ozkahya M, Zeytinoglu A, Nart D and Ok E: Risk factors and
consequences of post-transplant diabetes mellitus. Clin Transplant.
24:E170–E177. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ericzon B, Groth C, Bismuth H, Calne R,
McMaster P, Neuhaus P, Otto G, Pichlmayr R and Williams R: Glucose
metabolism in liver transplant recipients treated with FK 506 or
cyclosporin in the European multicentre study. Transplt Int.
7(Suppl 1): S11–S14. 1994. View Article : Google Scholar
|
|
7
|
Lohmann T, List C, Lamesch P, Kohlhaw K,
Wenzke M, Schwarz C, Richter O, Hauss J and Seissler J: Diabetes
mellitus and islet cell specific autoimmunity as adverse effects of
immun-suppressive therapy by FK506/tacrolimus. Exp Clin Endocrinol
Diabetes. 108:347–352. 2000. View Article : Google Scholar
|
|
8
|
Heit JJ, Apelqvist AA, Gu X, Winslow MM,
Neilson JR, Crabtree GR and Kim SK: Calcineurin/NFAT signalling
regulates pancreatic beta-cell growth and function. Nature.
443:345–349. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hernández-Fisac I, Pizarro-Delgado J,
Calle C, Marques M, Sánchez A, Barrientos A and Tamarit-Rodriguez
J: Tacrolimus-induced diabetes in rats courses with suppressed
insulin gene expression in pancreatic islets. Am J Transplant.
7:2455–2462. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rodriguez-Rodriguez AE, Triñanes J,
Porrini E, Velázquez-Garcia S, Fumero C, Vega-Prieto MJ,
Díez-Fuentes ML, Luis Lima S, Salido E and Torres A: Glucose
homeostasis changes and pancreatic β-cell proliferation after
switching to cyclosporin in tacrolimus-induced diabetes mellitus.
Nefrologia. 35:264–272. 2015.In English, Spanish.
|
|
11
|
Senior PA, Paty BW, Cockfield SM, Ryan EA
and Shapiro AM: Proteinuria developing after clinical islet
transplantation resolves with sirolimus withdrawal and increased
tacrolimus dosing. Am J Transplant. 5:2318–2323. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Desai NM, Goss JA, Deng S, Wolf BA,
Markmann E, Palanjian M, Shock AP, Feliciano S, Brunicardi FC,
Barker CF, et al: Elevated portal vein drug levels of sirolimus and
tacrolimus in islet transplant recipients: Local immunosuppression
or islet toxicity? Transplantation. 76:1623–1625. 2003. View Article : Google Scholar
|
|
13
|
Jahn I, Busch M, Ott U, Wolf G and
Battefeld W: Posttransplantation diabetes mellitus in patients
after kidney transplantation-Incidence and risk factors. Dtsch Med
Wochenschr. 141:e173–e182. 2016.In German. PubMed/NCBI
|
|
14
|
Liu JY, You RX, Guo M, Zeng L, Zhou P, Zhu
L, Xu G, Li J and Liu D: Tacrolimus versus cyclosporine as primary
immu-nosuppressant after renal transplantation: A meta-analysis and
economics evaluation. Am J Ther. 23:e810–e824. 2016. View Article : Google Scholar
|
|
15
|
Li Y, Goto T, Yamakuni K, Takahashi H,
Takahashi N, Jheng HF, Nomura W, Taniguchi M, Baba K, Murakami S
and Kawada T: 4-Hydroxyderricin, as a PPARγ agonist, promotes
adipogenesis, adiponectin secretion, and glucose uptake in 3T3-L1
cells. Lipids. 51:787–795. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Voytovich MH, Simonsen C, Jenssen T,
Hjelmesaeth J, Asberg A and Hartmann A: Short-term treatment with
rosiglitazone improves glucose tolerance, insulin sensitivity and
endothelial function in renal transplant recipients. Nephrol Dial
Transplant. 20:413–418. 2005. View Article : Google Scholar
|
|
17
|
Isokuortti E, Zhou Y, Peltonen M,
Bugianesi E, Clement K, Bonnefont-Rousselot D, Lacorte JM,
Gastaldelli A, Schuppan D, Schattenberg JM, et al: Use of HOMA-IR
to diagnose non-alcoholic fatty liver disease: A population-based
and inter-laboratory study. Diabetologia. 60:1873–1882. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bloom S, Ghatei M and Bech P: Measurement
of gut hormones in plasma. Methods. Mol Biol. 1065:147–170.
2013.
|
|
19
|
Pichaiwong W, Hudkins KL, Wietecha T,
Nguyen TQ, Tachaudomdach C, Li W, Askari B, Kobayashi T, O'Brien
KD, Pippin JW, et al: Reversibility of structural and functional
damage in a model of advanced diabetic nephropathy. J Am Soc
Nephrol. 24:1088–1102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arocho A, Chen B, Ladanyi M and Pan Q:
Validation of the 2-DeltaDeltaCt calculation as an alternate method
of data analysis for quantitative PCR of BCR-ABL P210 transcripts.
Diagn Mol Pathol. 15:56–61. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park S, Kim DS and Kang S: Vitamin D
deficiency impairs glucose-stimulated insulin secretion and
increases insulin resistance by reducing PPAR-γ expression in
nonobese type 2 diabetic rats. J Nutr Biochem. 27:257–265. 2016.
View Article : Google Scholar
|
|
22
|
Massaro M, Scoditti E, Pellegrino M,
Carluccio MA, Calabriso N, Wabitsch M, Storelli C, Wright M and De
Caterina R: Therapeutic potential of the dual peroxisome
proliferator activated receptor (PPAR)α/γ agonist aleglitazar in
attenuating TNF-α-mediated inflammation and insulin resistance in
human adipocytes. Pharmacol Res. 107:125–136. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dai C, Wang X, Wu Y, Xu Y, Zhuo S, Qi M,
Ji W and Zhan L: Polarity protein AF6 controls hepatic glucose
homeostasis and insulin sensitivity by modulating IRS1/AKT insulin
pathway in a SHP2-dependent manner. Diabetes. 68:1577–1590.
2019.PubMed/NCBI
|
|
24
|
Albaghdadi AJ, Hewitt MA, Putos SM, Wells
M, Ozolinš TR and Kan FW: Tacrolimus in the prevention of adverse
pregnancy outcomes and diabetes-associated embryopathies in obese
and diabetic mice. J Transl Med. 15:322017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gnatta D, Keitel E, Heineck I, Cardoso BD,
Rodrigues AP, Michel K and Garcia VD: Use of tacrolimus and the
development of posttransplant diabetes mellitus: A Brazilian
single-center, observational study. Transplant Proc. 42:475–478.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dabrowska-Zamojcin E, Tarnowski M,
Szydlowski M, Romanowski M, Dziedziejko V, Safranow K, Domanski L
and Pawlik A: KCNJ11 and KCNQ1 gene polymorphisms are not
associated with post-transplant diabetes mellitus in kidney
allograft recipients treated with tacrolimus. Folia Biol (Praha).
63:115–119. 2017.
|
|
27
|
Torres A, Hernández D, Moreso F, Serón D,
Burgos MD, Pallardó LM, Kanter J, Díaz Corte C, Rodríguez M, Diaz
JM, et al: Randomized controlled trial assessing the impact of
tacrolimus versus cyclosporine on the incidence of posttransplant
diabetes mellitus. Kidney Int Rep. 3:1304–1315. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jin J, Jin L, Luo K, Lim SW, Chung BH and
Yang CW: Effect of empagliflozin on tacrolimus-induced pancreas
islet dysfunction and renal injury. Am J Transplant. 17:2601–2616.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gachon F, Loizides-Mangold U, Petrenko V
and Dibner C: Glucose homeostasis: Regulation by peripheral
circadian clocks in rodents and humans. Endocrinology.
158:1074–1084. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Duijnhoven EM, Boots JM, Christiaans MH,
Wolffenbuttel BH and Van Hooff JP: Influence of tacrolimus on
glucose metabolism before and after renal transplantation: A
prospective study. J Am Society Nephrol. 12:583–588. 2001.
|
|
31
|
Terauchi Y and Kadowaki T: PPAR and
diabetes. Nihon Rinsho. 63:623–629. 2005.In Japanese. PubMed/NCBI
|
|
32
|
Holguin F, Rojas M and Hart CM: The
peroxisome proliferator activated receptor gamma (PPARgamma) ligand
rosiglitazone modulates bronchoalveolar lavage levels of leptin,
adiponectin, and inflammatory cytokines in lean and obese mice.
Lung. 185:367–372. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Azaïs H, Leroy A, Ghesquiere L, Deruelle P
and Hanssens S: Effects of adipokines and obesity on uterine
contractility. Cytokine Growth Factor Rev. 34:59–66. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jaganathan R, Ravindran R and Dhanasekaran
S: Emerging role of adipocytokines in type 2 diabetes as mediators
of insulin resistance and cardiovascular disease. Can J Diabetes.
42:446–456. e12018. View Article : Google Scholar
|
|
35
|
Kurian B, Joshi R and Helmuth A:
Effectiveness and long-term safety of thiazolidinediones and
metformin in renal transplant recipients. Endocr Pract. 14:979–984.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Villanueva G and Baldwin D: Rosiglitazone
therapy of posttrans-plant diabetes mellitus. Transplantation.
80:1402–1405. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gayet C, Leray V, Saito M, Siliart B and
Nguyen P: The effects of obesity-associated insulin resistance on
mRNA expression of peroxisome proliferator-activated receptor-gamma
target genes, in dogs. Br J Nutr. 98:497–503. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA,
Kim SG, Kim NH, Choi DS, Baik SH and Choi KM: Effect of PPAR-alpha
and -gamma agonist on the expression of visfatin, adiponectin, and
TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res
Commun. 336:747–753. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Blüher M and Paschke R: Analysis of the
relationship between PPAR-gamma 2 gene variants and severe insulin
resistance in obese patients with impaired glucose tolerance. Exp
Clin Endocrinol Diabetes. 111:85–90. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ruangkanchanasetr P, Sanohdontree N,
Supaporn T, Sathavarodom N and Satirapoj B: Beta cell function and
insulin resistance after conversion from tacrolimus twice-daily to
extended-release tacrolimus once-daily in stable renal transplant
recipients. Ann Transplant. 21:765–774. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhao J, Wang M, Deng W, Zhong D, Jiang Y,
Liao Y, Chen B and Zhang X: ADP-ribosylation factor-like GTPase 15
enhances insulin-induced AKT phosphorylation in the IR/IRS1/AKT
pathway by interacting with ASAP2 and regulating PDPK1 activity.
Biochem Biophys Res Commun. 486:865–871. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Moon MK, Kang GH, Kim HH, Han SK, Koo YD,
Cho SW, Kim YA, Oh BC, Park do J, Chung SS, et al:
Thyroid-stimulating hormone improves insulin sensitivity in
skeletal muscle cells via cAMP/PKA/CREB pathway-dependent
upregulation of insulin receptor substrate-1 expression. Mol Cell
Endocrinol. 436:50–58. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cignarelli A, Genchi VA, Perrini S,
Natalicchio A, Laviola L and Giorgino F: Insulin and insulin
receptors in adipose tissue development. Int J Mol Sci. 20:pii:
E759. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Roncero I, Alvarez E, Acosta C, Sanz C,
Barrio P, Hurtado-Carneiro V, Burks D and Blázquez E:
Insulin-receptor substrate-2 (irs-2) is required for maintaining
glucokinase and glucokinase regulatory protein expression in mouse
liver. PLoS One. 8:e587972013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bendickova K, Tidu F and Fric J:
Calcineurin-NFAT signalling in myeloid leucocytes: new prospects
and pitfalls in immunosup-pressive therapy. EMBO Mol Med.
9:990–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mathis AS, Jin S, Friedman GS, Peng F,
Carl SM and Knipp GT: The pharmacodynamic effects of sirolimus and
sirolimus-calcineurin inhibitor combinations on macrophage
scavenger and nuclear hormone receptors. J Pharm Sci. 96:209–222.
2007. View Article : Google Scholar
|
|
47
|
Aye IL, Gao X, Weintraub ST, Jansson T and
Powell TL: Adiponectin inhibits insulin function in primary
trophoblasts by PPARα-mediated ceramide synthesis. Mol Endocrinol.
28:512–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Boerner BP, Shivaswamy V, Wolatz E and
Larsen J: Post-transplant diabetes: Diagnosis and management.
Minerva Endocrinol. 43:198–211. 2018.
|
|
49
|
Li Z, Sun F, Zhang Y, Chen H, He N, Chen
H, Song P, Wang Y, Yan S and Zheng S: Tacrolimus induces insulin
resistance and increases the glucose absorption in the jejunum: A
potential mechanism of the diabetogenic effects. PLoS One.
10:e01434052015. View Article : Google Scholar : PubMed/NCBI
|
